Strategic Capital Alternatives’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Strategic Capital Alternatives’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$28K	Buy	+600	New	+$36.1K	0.01%	233

Other funds holding XPH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Hoxton Financial Shepherdstown, West Virginia $194M AUM 6.21% 1-Year Est. Return

Strategic Capital Alternatives's XPH Position: Q3 2015 in Review

Strategic Capital Alternatives opened a new position in State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q3 2015: 600 shares worth $28K. The stake represents 0.01% of the portfolio and ranks #233 among its holdings.

77 funds tracked by Wall St. Rank hold XPH as of Q3 2015.

Strategic Capital Alternatives held 600 shares of State Street SPDR S&P Pharmaceuticals ETF worth $28K as of Q3 2015.
State Street SPDR S&P Pharmaceuticals ETF was a new Strategic Capital Alternatives position in Q3 2015.
State Street SPDR S&P Pharmaceuticals ETF made up 0.01% of Strategic Capital Alternatives's portfolio in Q3 2015, its #233 holding.
77 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2015.

Based on Strategic Capital Alternatives's 13F filing for Q3 2015, filed 16 Nov 2015.